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Left Ventricular Hypertrophy (LVH) and Inhibition of Renin -Angiotensin System with ACE Inhibitor 
(ACEi) or Angiotensin Receptor Antagonist (AIIA) in Diabetic Patients on Dialysis Therapy
Keiko Kaneko ( Irumadai Clinic, Iruma -shi, Saitama 358 -0031, Japan )
Background: LVH is frequently found in diabetic and hypertensive patients at the initiation of dialysis therapy 
and is highly predictive of future cardiac morbidity and mortality. However, it is unknown whether the blockage 
of renin - angiotensin system will regress LVH or not in these patients using ACEi or AIIA or both of them in 
combination. Method: Twenty four diabetic patients (62±3 years old; F/M: 8/16) with end - stage renal disease 
who had just entered into hemodialysis therapy and were diagnosed as having LVH evaluated by echocardiography 
were selected from 5 dialysis units staffed by the faculty of Saitama Medical School, Saitama, Japan between 
1996 and 1998. The study was carried out for 2 years. An ACEi, enalapril 5 mg daily or an AIIA, losartan 50 mg 
daily was assigned at random. These drugs were administered 30 min after the cessation of dialysis therapy and 
usually given after lunch when dialysis therapy was not received. The doses of these drugs were adjusted up to 
10 mg or 100 mg daily respectively according to the levels of blood pressure. One year after the start of the study, 
if LVH was not regressed in spite of treatments with enalapril or losartan, add -on each other drug was done. 
Results: Using repeated measures analysis of variance, applied to those with four echocardiograms, there were 
progressive decreases over time in LV mass index (LVMi: g/m2), posterior wall thickness, left ventricle end -
diastolic diameter, interventricular thickness. The biggest changes in LVMi and other parameters found between 
the baseline and year 1 (147±14 vs. 138±12 g/m2). Combination therapy of enalapril and losartan for 7 patients 
who did not respond the initial therapy produced a significant reduction of LVH at the end of study. There was no 
significant difference in regression of LVH as well as blood pressure control and other variables between enalapril 
and losartan. Furthermore, there were significant correlations between the variables obtained from the repeated 
echocardiography related with LVH and systolic blood pressure in all patients. Conclusion: Antihypertensive 
treatment with either ACEi or AIIA is beneficial in the regression of LVH in diabetic patients who started dialysis 
therapy. Moreover, a combination therapy with ACEi and AIIA would provide a favorable effect on LVH in those 
patients unless a single administration of ACEi or AIIA is effective.
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じて有意差を認めなかった．第 1群で 140/90 mmHg 
以下になったものは 6例，第 2群では 9例であった．
12か月経過した時点でエナラプリルは 9例中 3例が
10 mgに増量され，ロサルタンは 12例中 8例が 100 
mgに増量されていた．またカルシウム拮抗薬は両群
のすべての患者に使われており，α1遮断薬は第 1群
で 4例，第 2群で 5例が使われていた．






れたデータ - - - 収縮期および拡張期での左室径，左室









量係数で男性は 130 g/m2，女性は 110 g/m2以上に加
えて左室後壁厚が 12 mm以上あるもの）の改善を認め






空腹時血糖値 146±25 mg/dlから 122±9 mg/dl，ヘモ
グロビン A1c8.1±0.6％から 6.5±0.7％，第 2群：空腹








Fig. 1. Serial changes in systolic blood pressure measured 
just before the star t of hemodialysis therapy in diabetic 
patients. ○ indicates the patients treated with an ACE 
inhibitor, enalapril and ● dose the patients treated with an 
AII antagonist, losartan. Systolic blood pressure gradually 
decreased and reached a significantly lower level at 4 months 
after the start of treatment. 
Fig. 2. Serial changes in diastolic blood pressure measured 
just before the star t of hemodialysis therapy in diabetic 
patients.  ○ indicates the patients treated with an ACE 
inhibitor, enalapril and ● dose the patients treated with an 
AII antagonist, losartan. Throughout the study, the levels 
of diastolic blood pressure did not show any significantly 
decreased.
Table 2.  Effects of treatment with ACE inhibitor or AII receptor antagonist on echocardiographic parameters in hypertensive 
type 2 diabetic patients on hemodialysis 
LVDd:Left ventricular diameter in diastole. LVDs:Left ventricular diameter in systole; PWT:  posterior wall thickness, 
IVST: Intraventricular septal thickness
LVMi: Left ventricular mass index, EF:Ejection fraction














いたのは 3例，またロサルタンが 100 mgに増量され
ていたのは 4例の全例であった．この 7名を対象とし
て第 1群にはロサルタンを 100 mg，第 2群にはエナラ











であったものが 2例，第 2群であったものが 2例で
Fig. 3. Serial changes in left ventricular mass index in the 
patients treated with an ACE inhibitor, enalapril (white 
column) and those treated with an AII antagonist, losartan 
(gray column). At 12 months after the start of the therapy, left 
ventricular mass index decreased significantly and there was 
no significant difference between two modalities. 
Table 3.  Effects of combination treatment with ACE inhibitor and AII receptor antagonist on echocardiographic parameters in 
hypertensive type 2 diabetic patients on hemodialysis 
LVDd:Left ventricular diameter in diastole. LVDs:Left ventricular diameter in systole; PWT:  posterior wall 
thickness, IVST: Intraventricular septal thickness
LVMi: Left ventricular mass index, EF:Ejection fraction
*p ＜0.05; Compared to the 0 month, Values: Mean±SEM.
Fig. 4. There was a significant dif ference in the doses of 
erythropoietin administered at the end of the first study 
between the patients treated with ACE inhibitor and those 














































































Fig. 5. Correlations between the systolic blood pressure 
before the routine dialysis therapy and left ventricular (LV) 
mass index of all patients participated in the present study 
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